Amendments to the Claims

Listing of Claims

- (Currently Amended) A method for treating and/or preventing Cardiovascular Diseasesacute coronary syndrome, high risk vascular disease or cerebrovascular ancurysm and recurrence thereof, in a patient in need thereof, comprising the following steps performed in any order:
 - a) administering a compound of formula I

or a pharmaceutically acceptable salt, solvate, active metabolite, prodrug, racemate or enantiomer thereof; and

- b) performing a PCI procedurepercutaneous coronary intervention procedure.
- (Currently Amended) A method for treating and/or preventing Cardiovascular Diseasesacute coronary syndrome, high risk vascular disease or cerebrovascular ancurysm and recurrence thereof, in a patient in need thereof, comprising the following steps performed in any order:
 - a) administering a compound of formula I

or a pharmaceutically acceptable salt, solvate, active metabolite, prodrug, racemate or enantiomer thereof in combination with aspirin; and

- performing a PCI procedure percutaneous coronary intervention procedure.
- (Currently Amended) A method for treating and/or preventing Cardiovascular Diseasesacute coronary syndrome, high risk vascular disease or cerebrovascular ancurysm and recurrence thereof, in a patient in need thereof, comprising the following steps performed in the order described:
 - a) first, administering a compound of formula I

or a pharmaceutically acceptable salt, solvate, active metabolite, prodrug, racemate or enantiomer thereof, optionally in combination with aspirin;

- second, performing a PCI procedurepercutaneous coronary intervention procedure; and
- c) third, administering a compound of formula I or a pharmaceutically acceptable salt, solvate, active metabolite, prodrug, racemate or enantiomer thereof, optionally in combination with aspirin.
- (Currently Amended) A method according to Claims 1, 2, or 3Claims 2 or 3 comprising in order the steps of:
- a) administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt, solvate, active metabolite, prodrug, recemate or enantiomer thereof, optionally in combination with aspirin or other eardio protective agent about 2 to 30 days prior to performing the PCI procedure percutaneous coronary intervention procedure.

Serial No. 10/553 763

- performing a PCI procedure percutaneous coronary intervention procedure, and
- c) administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt, solvate, active metabolite, prodrug, racemate or enantiomer thereof, optionally in combination with aspirin or other eardio protective agent about 0 to 365 days after performance of the PCI procedurencrecutaneous coronary intervention procedure.
- (Currently Amended) A method according to Claim 1, 2, or 3 wherein the compound of formula I, is 2-Acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride acid addition salt-or-enantiomer thereof.
 - (Cancelled)
 - 7. (Cancelled)
 - 8. (Cancelled)
 - 9. (Cancelled)
- 10. (Currently Amended) Use of a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, solvate, prodrug, active metabolite, racemate or enantiomer thereof, in conjunction with a stent for treating and/or preventing recurrence of eerebrovascular diseaseacute coronary syndrome.
 - 11. (Currently Amended) Use of a compound of formula I

or a pharmaceutically acceptable salt, solvate, prodrug, racemate or enantiomer thereof, in conjunction with a PCI procedure percutaneous coronary intervention Serial No. 10/553,763

<u>procedure</u> for treating and/or preventing the recurrence of <u>Cardiovascular</u>
<u>Diseasesacute coronary syndrome</u> comprising administering an effective amount of said compound <u>of formula I optionally in combination with aspirin</u> to a patient in need thereof.

- 12. (Cancelled)
- 13. (Cancelled)
- 14. (Cancelled)